| Recruiting | Phase Ib/IIa Clinical Study of ACC017 Tablets NCT06719310 | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461) NCT03368053 | GlaxoSmithKline | Phase 1 |
| Completed | GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers NCT03231943 | ViiV Healthcare | Phase 1 |
| Completed | Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex W NCT03310515 | ViiV Healthcare | — |
| Completed | A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Asses NCT03234036 | GlaxoSmithKline | Phase 1 |
| Completed | Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects NCT03149848 | ViiV Healthcare | Phase 1 |
| Completed | Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine NCT03078556 | ViiV Healthcare | Phase 1 |
| Completed | Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults NCT03045861 | GlaxoSmithKline | Phase 2 |
| Completed | Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers NCT02478463 | ViiV Healthcare | Phase 1 |
| Completed | Phase 4 Study of Dolutegravir (DTG) in Russian Federation NCT03314064 | ViiV Healthcare | Phase 4 |
| Active Not Recruiting | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-act NCT02951052 | ViiV Healthcare | Phase 3 |
| Completed | Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet NCT02893488 | ViiV Healthcare | Phase 1 |
| Completed | A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended- NCT02859259 | ViiV Healthcare | Phase 1 |
| Completed | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Teno NCT02831673 | ViiV Healthcare | Phase 3 |
| Completed | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegrav NCT02831764 | ViiV Healthcare | Phase 3 |
| Unknown | Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3T NCT03275701 | Mills Clinical Research | N/A |
| Completed | A Study to Evaluate the Effect of High Fat Meal on Cabotegravir NCT02799264 | ViiV Healthcare | Phase 1 |
| Completed | Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) NCT02741557 | ViiV Healthcare | Phase 1 |
| Completed | Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations NCT02738931 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravi NCT02715479 | ViiV Healthcare | Phase 1 |
| Completed | Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing NCT02805556 | ViiV Healthcare | Phase 1 |
| Completed | Single and Repeated Dose Escalation Study of GSK2838232 NCT02795754 | GlaxoSmithKline | Phase 1 |
| Completed | A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended R NCT02666053 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone NCT02666001 | ViiV Healthcare | Phase 1 |
| Completed | A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sor NCT02634073 | ViiV Healthcare | Phase 4 |
| Terminated | A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects NCT02576119 | ViiV Healthcare | Phase 1 |
| Completed | Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination T NCT02539576 | ViiV Healthcare | Phase 1 |
| Completed | Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part NCT02508064 | ViiV Healthcare | Phase 1 |
| Completed | Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment NCT02354937 | ViiV Healthcare | Phase 1 |
| Completed | A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI) NCT02480881 | ViiV Healthcare | Phase 1 |
| Completed | A Open-label, Drug-Drug Interaction With Maraviroc (DDI) NCT02480894 | ViiV Healthcare | Phase 1 |
| Completed | Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects NCT02411435 | ViiV Healthcare | Phase 1 |
| Terminated | Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults NCT02415595 | ViiV Healthcare | Phase 2 |
| Completed | Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir NCT02345707 | ViiV Healthcare | Phase 1 |
| Completed | Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in He NCT02373930 | ViiV Healthcare | Phase 1 |
| Completed | Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Co NCT02467335 | ViiV Healthcare | Phase 1 |
| Completed | Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosi NCT02178592 | ViiV Healthcare | Phase 3 |
| Completed | ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection NCT02075593 | ViiV Healthcare | Phase 3 |
| Terminated | A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted i NCT02289495 | GlaxoSmithKline | Phase 1 |
| Terminated | A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted i NCT02289482 | GlaxoSmithKline | Phase 1 |
| Completed | A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) NCT02277600 | ViiV Healthcare | Phase 1 |
| Completed | Food Effect Study With BMS-955176 NCT02273947 | ViiV Healthcare | Phase 1 |
| Completed | Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispe NCT02185300 | ViiV Healthcare | Phase 1 |
| Completed | Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 NCT02164045 | ViiV Healthcare | Phase 1 |
| Completed | Study of Combined Oral Contraceptive Effects in Female Subjects NCT02157467 | ViiV Healthcare | Phase 1 |
| Completed | Drug-drug Interaction (DDI) Rifabutin NCT02138084 | ViiV Healthcare | Phase 1 |
| Completed | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Fo NCT02120352 | ViiV Healthcare | Phase 2 |
| Completed | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abaca NCT02105987 | ViiV Healthcare | Phase 3 |
| Completed | Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodefic NCT02076178 | ViiV Healthcare | Phase 2 |
| Completed | Relative Bioavailability Study With BMS-955176 NCT02095886 | ViiV Healthcare | Phase 1 |
| Completed | A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Thera NCT02076386 | ViiV Healthcare | — |
| Completed | Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subje NCT02082808 | ViiV Healthcare | Phase 1 |
| Completed | DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV) NCT02063360 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subje NCT02059031 | ViiV Healthcare | Phase 1 |
| Completed | Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects NCT02064374 | ViiV Healthcare | Phase 1 |
| Completed | Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction NCT02027454 | ViiV Healthcare | Phase 1 |
| Completed | Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects NCT01967771 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodefi NCT01910402 | ViiV Healthcare | Phase 3 |
| Completed | Study to Evaluate a HIV Drug for the Treatment of HIV Infection NCT01803074 | ViiV Healthcare | Phase 2 |
| Completed | Single Dose Escalation Study of GSK2838232 in Healthy Subjects NCT01802918 | GlaxoSmithKline | Phase 1 |
| Completed | A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parent NCT01754116 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir NCT01762995 | ViiV Healthcare | Phase 1 |
| Completed | Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immun NCT01641809 | ViiV Healthcare | Phase 2 |
| Completed | Dolutegravir Expanded Access Study NCT01536873 | ViiV Healthcare | N/A |
| Completed | Evaluation of the Bioequivalence of a Combined Formulated Tablet NCT01622790 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Act NCT01593046 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult NCT01563328 | ViiV Healthcare | Phase 1 |
| Completed | A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 NCT01499199 | ViiV Healthcare | Phase 3 |
| Completed | Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestra NCT01498861 | ViiV Healthcare | Phase 1 |
| Completed | Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase NCT01449929 | ViiV Healthcare | Phase 3 |
| Completed | Drug Interaction Study Between Dolutegravir and Prednisone NCT01425099 | ViiV Healthcare | Phase 1 |
| Completed | HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections NCT01384734 | ViiV Healthcare | Phase 2 |
| Completed | Dolutegravir Renal Impairment Study NCT01353716 | ViiV Healthcare | Phase 1 |
| Completed | Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets NCT01366547 | ViiV Healthcare | Phase 1 |
| Completed | Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349 NCT01231542 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Conta NCT01328041 | ViiV Healthcare | Phase 3 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Heal NCT01332565 | ViiV Healthcare | Phase 1 |
| Withdrawn | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral NCT01273103 | ViiV Healthcare | Phase 1 |
| Completed | GSK1349572 Hepatic Impairment Study NCT01231529 | ViiV Healthcare | Phase 1 |
| Terminated | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) NCT01231555 | ViiV Healthcare | Phase 2 |
| Completed | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral NCT01231516 | ViiV Healthcare | Phase 3 |
| Terminated | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infec NCT01199731 | ViiV Healthcare | Phase 2 |
| Terminated | A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Heal NCT01195974 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. NCT01209117 | ViiV Healthcare | Phase 1 |
| Completed | A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects. NCT01138072 | GlaxoSmithKline | Phase 1 |
| Completed | A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects NCT01101893 | ViiV Healthcare | Phase 1 |
| Completed | GSK1349572 Relative Bioavailability Study NCT01098513 | ViiV Healthcare | Phase 1 |
| Completed | A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) NCT01102972 | ViiV Healthcare | Phase 4 |
| Completed | Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers NCT01068925 | ViiV Healthcare | Phase 1 |
| Completed | A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761 NCT01031472 | ViiV Healthcare | Phase 1 |
| Completed | Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Inf NCT00945282 | ViiV Healthcare | Phase 2 |
| Completed | A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Ral NCT00950859 | ViiV Healthcare | Phase 2 |
| Completed | A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects NCT00951015 | ViiV Healthcare | Phase 2 |
| Completed | DDI Study of Etravirine and GSK1265744 NCT00920296 | GlaxoSmithKline | Phase 1 |
| Completed | Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ1129 NCT00920426 | ViiV Healthcare | Phase 2 |
| Completed | Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs NCT00920088 | GlaxoSmithKline | Phase 1 |
| Completed | HIV Treatment and CVD Events NCT01054638 | ViiV Healthcare | — |
| Completed | Fosamprenavir in Pts With Hepatic Impairment NCT01054586 | GlaxoSmithKline | — |
| Completed | PENTA Fosamprenavir Study NCT01077635 | ViiV Healthcare | — |
| Completed | GSK1349572 Drug Interaction Study With Protease Inhibitors NCT00774735 | GlaxoSmithKline | Phase 1 |
| Completed | GSK706769/KALETRA Drug-drug Interaction Study NCT00723775 | GlaxoSmithKline | Phase 1 |
| Completed | Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults NCT00708110 | ViiV Healthcare | Phase 2 |
| Completed | Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Faste NCT00812318 | ViiV Healthcare | Phase 1 |
| Completed | GSK706769 Repeat Dose Study NCT00711386 | GlaxoSmithKline | Phase 1 |
| Completed | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 NCT00453440 | ViiV Healthcare | — |
| Completed | Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients NCT00441688 | ViiV Healthcare | Phase 4 |
| Completed | Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults NCT00398125 | GlaxoSmithKline | Phase 2 |
| Completed | Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status NCT01077557 | ViiV Healthcare | — |
| Completed | A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects. NCT00386347 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects NCT00363142 | GlaxoSmithKline | Phase 3 |
| Completed | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks NCT00085943 | GlaxoSmithKline | Phase 3 |
| Completed | Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects NCT00071760 | ViiV Healthcare | Phase 2 |
| Completed | Fosamprenavir Expanded Access NCT00240552 | ViiV Healthcare | Phase 4 |
| Completed | A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects NCT00296504 | ViiV Healthcare | Phase 3 |
| No Longer Available | An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc NCT01776996 | ViiV Healthcare | — |
| Available | GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV NCT03462810 | ViiV Healthcare | — |